Related Experiment Video
Updated: Jun 24, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Urolithiasis with topiramate in nonambulatory children and young adults
Monisha Goyal1, Richard I Grossberg, Mary Ann O'Riordan
1Pediatric Neurology Department, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio, USA. Monisha.Goyal@uhhospitals.org
Insights
Topiramate, an antiepileptic drug, significantly increases kidney stone risk in neurologically impaired individuals. This population experienced a 54% urolithiasis rate, much higher than previously reported.
Area of Science:
- Nephrology
- Neurology
- Pharmacology
Background:
- Urolithiasis is uncommon in children, often linked to metabolic factors.
- Topiramate, an antiepileptic, has a known 1.5% kidney stone risk in clinical trials.
- This risk may be elevated in specific patient groups with pre-existing conditions.
Purpose of the Study:
- To investigate the incidence of urolithiasis in nonambulatory, neurologically impaired individuals.
- To assess the association between topiramate use and kidney stone development in this high-risk population.
Main Methods:
- Retrospective review of patients in a long-term care facility.
- Categorization into three groups: no antiepileptic drugs, non-topiramate antiepileptics, and topiramate users.
- Analysis of clinical urolithiasis development over a mean of 36.4 months.
Main Results:
- Thirteen out of 24 (54%) individuals on topiramate developed urolithiasis.
- This incidence is substantially higher than the general reported risk of 1.5%.
Conclusions:
- Nonambulatory and neurologically impaired individuals in long-term care are at a significantly increased risk of topiramate-associated urolithiasis.
- Clinical vigilance for kidney stones is crucial in this population undergoing topiramate treatment.
Abstract:
Urolithiasis occurs infrequently in the pediatric population, where metabolic factors play a primary role in the pathogenesis of stone formation. Topiramate, an antiepileptic drug, is associated with a kidney stone in 1.5% of patients in published clinical trials. However, this risk may be much higher in certain populations with multiple preexisting risk factors. We performed a retrospective review of all nonambulatory and neurologically impaired individuals in a long-term care facility. Three groups were involved: those with no exposure to antiepileptic drugs, those on antiepileptic drugs other than topiramate, and those who had been treated with topiramate. Thirteen of 24 (54%) individuals on topiramate monotherapy or polytherapy developed clinical evidence of urolithiasis after a mean duration of 36.4 months. Our results suggest that nonambulatory and neurologically impaired individuals in a long-term care facility appear to be at higher risk of developing kidney stones with topiramate than previously reported.
Related Concept Videos
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi V: Nursing Management
Urinary Tract Calculi I: Introduction
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Urinary Tract Calculi VI: Surgical Management